$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Medical drugs
Medical drugs
Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Whether sparsentan (sparsentan) needs to be taken continuously and the discontinuation plan
2026-02-01 22:25:32
Check Details
Detailed explanation of Ixazomib (Enleri) onset time and treatment course observation recommendations
2026-02-01 22:25:32
Check Details
Analysis of indications and clinical application scope of rubitin/rubicatin (Zanbiga)
2026-02-01 22:25:32
Check Details
The latest research progress and future clinical application prospects of Pimitespib
2026-02-01 22:25:32
Check Details
Afatinib (Gitairin) drug interactions and precautions for co-administration
2026-02-01 22:25:32
Check Details
Analysis of patients’ real medication experience and effect feedback of DaliRasen (Keweike)
2026-02-01 22:25:32
Check Details
Comparative analysis of the efficacy and safety of Lynparza and Pamiparib
2026-02-01 22:25:32
Check Details
Venetoclax/Venetoclax (Vekela) contraindications and instructions for those who should take it with caution
2026-02-01 22:25:32
Check Details
Possible drug resistance to Asnib/Aximinib (Sinbel) and treatment options for worsening
2026-02-01 22:25:32
Check Details
Detailed description of the storage conditions and drug preservation methods of Ritexitinib (Lefenox)
2026-02-01 22:25:32
Check Details
Comprehensive interpretation of the indications and clinical scope of sparsentan (sparsentan)
2026-02-01 22:25:32
Check Details
Ixazomib (Ixazomib) foreign generic drug prices and purchasing reference information
2026-02-01 22:25:32
Check Details
1
2
...
2207
2208
2209
2210
2211
2212
2213
...
2438
2439
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Olaparib Plus Pembrolizumab Maintenance Therapy for Metastatic Pancreatic Cancer: Findings from the POLAR Phase II Basket Trial
2
From Causes to Treatments—Exploring Medical Breakthroughs
3
IRX4 Transcription Factor: New Research Insights on Colorectal Cancer Treatment Targets
4
New Research Progress on Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Tumor Relationship
5
Tyrosine Kinase and JAK Inhibitors May Increase Keratinocyte Carcinoma Risk: New Research Reveals Drug Safety Findings
6
CLISGen Database: A New Tool for Cell Line Selection in Cancer Genetic Variation Research
7
RAS Targeted Therapy Resistance Breakthrough: mTORC1 is Key, Dalifarnib Combination Therapy Brings Hope
8
ARID1A Gene: A New Breakthrough in Tumor Immunotherapy, Turning "Cold Tumors" Hot
9
User Agreement
10
Herceptin Hylecta treats HER2-positive breast cancer and only needs to be injected subcutaneously and only used once every three weeks
11
What is the most important information I should know about WELIREG?
12
How to take and store WELIREG